Can Wegovy Make You Light-Headed or Dizzy?

What Wegovy's clinical programme found about dizziness

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults and tracked semaglutide 2.4mg over 68 weeks against placebo. Dizziness appeared among the recorded adverse events in the active-treatment group, clustered most heavily in the dose-escalation phase when the body is adapting to rising semaglutide levels. The trial's overall pattern was consistent with what clinicians now see in practice: gastrointestinal effects dominate the early side-effect profile, and dizziness often follows in their wake rather than arriving on its own.

Why the two are linked matters. Nausea, reduced appetite and vomiting can all reduce how much a person eats and drinks during the first weeks on Wegovy. Mild dehydration, combined with lower calorie intake, can drop blood pressure slightly, particularly on standing. That transient fall is enough to produce the brief swimming sensation many people describe. It is orthostatic rather than neurological in most cases, which is reassuring, but it still needs to be taken seriously if it is happening regularly.

The NHS medicines information for semaglutide lists dizziness explicitly as a side effect that affects more than one in a hundred people, placing it in the "common" category. That classification means it is well within the expected range and not a signal that something has gone wrong with your specific prescription.

Why light-headedness tends to peak early and then settle

A question our prescribers hear most weeks is whether the dizziness felt in the first month means the medicine is wrong for them. In most cases it does not. Semaglutide starts at 0.25mg and steps up approximately every four weeks; each step can briefly repeat the adjustment effect that made the early weeks uncomfortable.

The practical picture is this: appetite suppression means smaller meals, smaller meals mean less carbohydrate, and falling carbohydrate intake alongside reduced fluid can produce a blood-pressure dip on standing. Standing up quickly from a chair or getting out of bed is the most common moment people notice it. Rising slowly, keeping fluid intake steady even when hunger fades, and eating small portions regularly through the day all help. These are not workarounds; they are part of the lifestyle adjustments that the medicine is designed to support.

People on antihypertensives, diuretics or other medicines affecting blood pressure carry a higher baseline risk of this effect. If that describes your situation, it is worth reading about how Wegovy works and what affects the experience of treatment before you start, and flagging it with whoever is prescribing.

When dizziness needs medical attention, not reassurance

Mild, brief light-headedness that clears in seconds is different from dizziness that is severe, that leads to fainting, or that comes with chest pain, sudden visual changes or difficulty speaking. The latter are not typical Wegovy side effects and need same-day medical assessment, ideally by calling 111 or attending A&E if symptoms are acute.

Persistent dizziness that does not ease between dose increases is also worth reporting rather than tolerating. A prescriber can review whether the titration pace suits you, check whether concurrent medicines are contributing, or assess hydration. The MHRA's Yellow Card scheme exists precisely so that side-effect patterns are monitored across the whole population on a medicine, not just in trials; any suspected side effect can and should be reported there.

The question of whether semaglutide can make you light-headed in ways beyond the short-term adjustment period is less settled. There are individual cases of people who find dizziness persists at certain doses; for them, a dose pause or slower titration is a clinical option. That kind of decision sits with the prescriber, not the patient acting alone. If you are considering Wegovy and want to understand how the process works before you start, our treatment page explains what a clinical assessment with our prescribers involves.

Light-headedness in context: keeping the risk in proportion

None of this is a reason to avoid treatment if a prescriber has assessed you as a suitable candidate. Dizziness ranks well below nausea and gastrointestinal discomfort in the frequency tables for Wegovy, and the majority of people who experience it find it resolves without any change to their prescription.

The broader evidence base for semaglutide, including the EMA's regulatory assessment, is extensive and consistently shows that the medicine's benefits in weight management, for people who meet the licensed criteria, significantly outweigh its side-effect burden for most. That balance looks different for each person depending on their medical history, other medicines and lifestyle, which is exactly why individual prescriber review matters.

If you have questions about whether Wegovy can affect your weight in unexpected ways, the FAQs section covers common practical queries, including whether semaglutide can be made or sourced outside of a licensed supply chain. For anything specific to your health history, a consultation is the right next step. Our prescribers at the nume clinical team review every consultation personally and are available to discuss concerns like these as part of the assessment.